Asymmetry Capital Management L.P. cut its holdings in shares of Heron Therapeutics (NASDAQ:HRTX) by 22.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 77,346 shares of the biotechnology company’s stock after selling 21,835 shares during the quarter. Heron Therapeutics makes up approximately 2.7% of Asymmetry Capital Management L.P.’s holdings, making the stock its 13th largest holding. Asymmetry Capital Management L.P.’s holdings in Heron Therapeutics were worth $2,135,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Swiss National Bank increased its holdings in Heron Therapeutics by 25.5% during the 4th quarter. Swiss National Bank now owns 98,500 shares of the biotechnology company’s stock worth $1,783,000 after purchasing an additional 20,000 shares during the last quarter. Ellington Management Group LLC purchased a new stake in Heron Therapeutics during the 4th quarter worth approximately $195,000. Geode Capital Management LLC increased its holdings in Heron Therapeutics by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 397,456 shares of the biotechnology company’s stock worth $7,193,000 after purchasing an additional 2,410 shares during the last quarter. Teacher Retirement System of Texas purchased a new stake in Heron Therapeutics during the 4th quarter worth approximately $272,000. Finally, Deutsche Bank AG increased its holdings in Heron Therapeutics by 9.8% during the 4th quarter. Deutsche Bank AG now owns 440,862 shares of the biotechnology company’s stock worth $7,976,000 after purchasing an additional 39,336 shares during the last quarter. Institutional investors own 96.35% of the company’s stock.

In related news, Director Kevin C. Tang acquired 192,308 shares of Heron Therapeutics stock in a transaction that occurred on Thursday, March 29th. The stock was acquired at an average price of $26.00 per share, for a total transaction of $5,000,008.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Kimberly Manhard sold 18,000 shares of the business’s stock in a transaction that occurred on Monday, March 19th. The shares were sold at an average price of $30.00, for a total value of $540,000.00. Following the transaction, the vice president now owns 18,000 shares of the company’s stock, valued at approximately $540,000. The disclosure for this sale can be found here. Insiders have sold a total of 218,000 shares of company stock valued at $5,990,000 in the last 90 days. Insiders own 19.93% of the company’s stock.

Several equities research analysts have issued reports on HRTX shares. BidaskClub upgraded Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 20th. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Friday, March 2nd. Oppenheimer set a $27.00 target price on Heron Therapeutics and gave the stock a “buy” rating in a research report on Thursday, March 1st. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 target price (up previously from $28.00) on shares of Heron Therapeutics in a research report on Thursday, March 1st. Finally, Cantor Fitzgerald set a $31.00 target price on Heron Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Heron Therapeutics currently has a consensus rating of “Buy” and an average target price of $36.54.

Shares of Heron Therapeutics opened at $32.10 on Thursday, according to MarketBeat. The company has a market capitalization of $2.33 billion, a PE ratio of 8.79 and a beta of 1.88. Heron Therapeutics has a 52 week low of $30.95 and a 52 week high of $31.85.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.06. Heron Therapeutics had a negative return on equity of 239.94% and a negative net margin of 515.27%. The business had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.10 million. The business’s quarterly revenue was up 222.2% compared to the same quarter last year. research analysts expect that Heron Therapeutics will post -2.4 earnings per share for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.